infertility prevention project region i wells, maine june 6-7, 2011
DESCRIPTION
Infertility Prevention Project Region I Wells, Maine June 6-7, 2011. Steven J Shapiro. Infertility Prevention Project Coordinator Program and Training Branch. National Center for HIV/AIDS, Viral Hepatitis, STD & TB Prevention. Division of STD Prevention. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/1.jpg)
Steven J ShapiroInfertility Prevention Project Coordinator
Program and Training Branch
Infertility Prevention ProjectRegion I
Wells, MaineJune 6-7, 2011
National Center for HIV/AIDS, Viral Hepatitis, STD & TB PreventionDivision of STD Prevention
![Page 2: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/2.jpg)
TopicsNational Infertility Prevention Project
CSPS 2011 and 2012 DSTDP Update Health Care Reform Gonorrhea
![Page 3: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/3.jpg)
CSPS 2011 2011
@2010 levels -70/30 Awards• A 0.2% Rescission
Additional Funds -1.546 million dollars in FY 2010• $118K National Chlamydia Coalition• $190K Infrastructure Shortfall• $500K “The Future of IPP”• $730K Supplemental IPP Project Area Funds
o Expansion of CT/GC screening and treatment services
![Page 4: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/4.jpg)
CSPS 2012 2012
@2010 levels Application Due August 2, 2011 Streamlined Application
• All requirements from FOA 09-902 remain in forceo Title X grantee Letter(s)o 3% Chlamydia Positivityo Targeted Gonorrhea Plans with Burden Calculationo Progress on General IPP Objectives
• Performance Measures Additional Guidance
• National Conference• Regional IPP Meetings• IPP Program Plans
![Page 5: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/5.jpg)
GC Burden Calculation - Example Project Area X
Total IPP Funds = $500,000 Among women 25 and younger [ALL]
• 500 Gonorrhea and 10,000 Chlamydia• GC Burden = [500/(10000+500)] X 100 = 4.76%
IPP Funds to be used• $500,000 X 4.76% = $23,800• @ $10/test = 2380 tests available for targeting
![Page 6: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/6.jpg)
DSTDP Update Personnel Changes Current Activities
PCSI Data Security and Confidentiality Guidelines Antibiotic-resistant Gonorrhea Outbreak response plan
Publications• GISP Profiles• Community Approaches to Reducing STD• CDC Grand Rounds- Chlamydia Prevention• NG with Reduced Susceptibility to Azithromycin- San Diego• DCL- Azithromycin Resistance in Hawaii
![Page 7: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/7.jpg)
Health Care Reform
![Page 8: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/8.jpg)
Health Care Reform Key Issues
Affordable Care Act and Performance Improvement National HIV/AIDS Strategy Agency Winnable Battles (HIV, Teen Pregnancy
Prevention)
“The Future of IPP” An Infrastructure-driven Evaluation
• IPP in the Project Areas• Environmental Scan• Recommendations for the Future
![Page 9: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/9.jpg)
“The Future of STD Prevention”2012 and Beyond
Assurance Functioning Surveillance Systems Local Epidemiology Support PCSI
Policy Development Plan Programs using Data- all sorts of data
Assessment and Accountability Monitoring Evaluation
Safety Net Coverage
![Page 10: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/10.jpg)
DRIP, DRIP, DRIP……
![Page 11: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/11.jpg)
Gonorrhea—Rates by Age Among Women Aged 15–44 Years, United States, 2000–2009
Rate (per 100,000 population)
Year
0
200
400
600
800
1,000
2009200820072006200520042003200220012000
35–3940–44
30–34
25–2920–2415–19
Age Group
![Page 12: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/12.jpg)
Gonorrhea—Rates by Age Among Men Aged 15–44 Years, United States, 2000–2009
0
150
300
450
600
750
2009200820072006200520042003200220012000
Rate (per 100,000 population)
Year
35–3940–44
30–34
25–2920–2415–19
Age Group
![Page 13: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/13.jpg)
Gonorrhea—Rates by Race/Ethnicity, United States,
2000–2009
0
100
200
300
400
500
600
700
800
2009200820072006200520042003200220012000
WhitesHispanicsBlacks
Asians/Pacific IslandersAmerican Indians/Alaska Natives
Rate (per 100,000 population)
Year
![Page 14: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/14.jpg)
Gonorrhea—Rates by County, United States, 2009
<19.0 (n = 1,405)
Rate per 100,000population
19.1–100.0 (n = 1,129)>100.0 (n = 607)
![Page 15: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/15.jpg)
IS GONORRHEA DECREASING?
![Page 16: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/16.jpg)
NATIONAL JOB TRAINING PROGRAM SCREENING DATA
![Page 17: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/17.jpg)
National Job Training Screening Program
National Job Training Program (NJTP) Federally funded job preparatory program Economically disadvantaged men and women aged 16–
24 years 48 states and Washington, DC
Gonorrhea screening required at entry Contract laboratory performs tests Laboratory data shared with CDC Includes information on both positive and negative tests
Available information Sex, age, race/ethnicity Test technology Place and date tested
![Page 18: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/18.jpg)
Why use NJTP data ? Information is available on all GC tests
Prevalence = XXX – number of people testing positive XXX – all people tested upon entry to
NJTP
Large, “stable” population 95,184 men tested for GC from 2004-2009 91,697 women tested for GC from 2004-2009 Consistent demographic each year
NJTP entrants have higher GC risk than U.S. population >70% < 19 years old >60% black >50% from South
![Page 19: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/19.jpg)
Gonorrhea prevalence among men screened in the National Job Training
Program
80
180
280
380
480
580
680
0
0.5
1
1.5
2
2.5
3
3.5
2005 2006 2007 2008 2009
Case
rate
per
100
,000
per
sons
in N
ETSS
Perc
ent G
C po
sitive
in N
JTP
N= 95,184
GC prevalence Case rates in 15-24 year olds (NETSS)
![Page 20: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/20.jpg)
Gonorrhea prevalence among women screened in the National Job Training
Program
80
180
280
380
480
580
680
0
0.5
1
1.5
2
2.5
3
3.5
2005 2006 2007 2008 2009
Case
rate
per
100
,000
per
sons
in N
ETSS
Perc
ent G
C po
sitive
in N
JTP
N= 91,697
GC prevalence Case rates in 15-24 year olds (NETSS)
![Page 21: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/21.jpg)
Racial disparities among women in the National Job Training Program and
NETSS
Black
HispanicWhite
00.5
11.5
22.5
33.5
44.5
5
2005 2006 2007 2008 2009
GC P
reva
lenc
e
Year
GC prevalence by race/ethnicity among women screened in the National Job Training Program
White
Black
Hispanic
0
100
200
300
400
500
600
2005 2006 2007 2008 2009
Rate
per
100
,000
per
sons
Year
GC case rates among women in NETSS by race/ethnicity
![Page 22: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/22.jpg)
NETSS DATA-TRENDS
![Page 23: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/23.jpg)
Gonorrhea trends by project area, 2005–2010*
Large decrease
Moderatedecrease
Flat Moderateincrease
Largeincrease
![Page 24: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/24.jpg)
BUT*…………. Significant Increases
L.A. 14% San Francisco 10% CPA 16% Hawaii 15% New Mexico 16% Massachusetts 26% Washington 25% Puerto Rico 35% NYC 15% New Jersey 21% Philadelphia 40% Pennsylvania 20% Maryland 20% Baltimore 10%
Maine 13%Massachusetts 26%New Hampshire 36%Vermont 14%
Connecticut <1%Rhode Island 9%
*NETSS DATA April 28 2011 (CY 2009-CY 2010)
![Page 25: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/25.jpg)
Gonorrhea trends by project area, 2009–2010*
Large decrease
Moderatedecrease
Flat Moderateincrease
Largeincrease
![Page 26: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/26.jpg)
RESISTANCE MDR GC
![Page 27: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/27.jpg)
“The one who does not remember history is bound to live through it again.”
George Santayana
![Page 28: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/28.jpg)
“The one who does not remember history is bound to live through it again.”
“Even those who remember history are still gonna be stuck living through it again.”
George Santayana
The gonococcus
![Page 29: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/29.jpg)
GONOCOCCAL ISOLATE SURVEILLANCE PROJECT DATA
![Page 30: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/30.jpg)
Phoenix Albuquerque
Dallas
San DiegoOrange Co.
Las Vegas
Portland
NewOrleans
Honolulu
San Francisco
Minneapolis
Philadelphia
Cincinnati BaltimoreChicago
Miami
Denver
AtlantaBirmingham
Seattle
Cleveland
BirminghamRegional Labs
AtlantaSeattleCleveland
Tripler AMC
Los Angeles Greensboro
Detroit
OklahomaCity
New YorkCity
Kansas City
Richmond
GISP sites and regional laboratories —
United States, 2010 (29 Sites)
Austin*
* Funded for FY2010 & FY2011 as regional lab, not yet functioning
Austin
![Page 31: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/31.jpg)
Emergence of FQ Resistance: Hawaii
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
05
1015202530354045
Cipro available
Reports of FQ resistance
* CDC, MMWR 2000.
FQ not recommended for GC in Hawaii*
Perc
enta
ge o
f GIS
P is
olat
es r
esis
tant
to
cipr
oflox
acin
Hawaii
![Page 32: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/32.jpg)
Emergence of FQ Resistance: California
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
05
1015202530354045
Hawaii*
California
Perc
enta
ge o
f GIS
P is
olat
es r
esis
tant
to
cipr
oflox
acin
* CDC, MMWR 2000; ** CDC, MMWR, 2002
FQ not recommended for GC in California**
![Page 33: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/33.jpg)
Emergence of FQ Resistance:
MSM
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
05
1015202530354045 FQ not recommended for
MSM†
Perc
enta
ge o
f GIS
P is
olat
es r
esis
tant
to
cipr
oflox
acin
MSM
Hawaii*California**
* CDC, MMWR 2000; ** CDC, MMWR, 2002; † CDC, MMWR, 2004.
![Page 34: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/34.jpg)
Emergence of FQ Resistance: Rest of the US (Excluding Hawaii & California)
1984
1986
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
05
1015202530354045
US
Hawaii* MSM†
California**
* CDC, MMWR 2000; ** CDC, MMWR, 2002; † CDC, MMWR, 2004.; ‡ CDC, MMWR, 2007.
FQ not recommended in US‡
Perc
enta
ge o
f GIS
P is
olat
es r
esis
tant
to
cipr
oflox
acin
![Page 35: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/35.jpg)
GISP TRENDS
![Page 36: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/36.jpg)
Distribution of MICs to Cefixime, 2005–2010*
0.015 0.03 0.06 0.125 0.25 0.50
102030405060708090
20052006
Perc
enta
ge o
f iso
late
s
Minimum Inhibitory Concentrations (MICs), µg/ml* Preliminary (Jan-Sept)
![Page 37: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/37.jpg)
Distribution of MICs to Cefixime, 2005–2010*
0.06 0.125 0.25 0.50
1
2
3
4
5
6
7
20052006
Perc
enta
ge o
f iso
late
s
Minimum Inhibitory Concentrations (MICs), µg/ml
1.3%
(n=58)
0.2%
(n=8)
* Preliminary (Jan-Sept)
GISP Surveillance
“alerts”“Decreased
Susceptibility”
![Page 38: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/38.jpg)
Distribution of MICs to Ceftriaxone, 2006–2010*
0.06 0.125 0.25 0.50
0.5
1
1.5
2
2.5
320062007200820092010*
Perc
enta
ge o
f iso
late
s
Minimum Inhibitory Concentrations (MICs), µg/ml* Preliminary (Jan-Sept)
![Page 39: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/39.jpg)
Distribution of MICs to Ceftriaxone, 2006–2010*
0.06 0.125 0.25 0.50
0.5
1
1.5
2
2.5
320062007200820092010*
Perc
enta
ge o
f iso
late
s
Minimum Inhibitory Concentrations (MICs), µg/ml* Preliminary (Jan-Sept)
GISP Surveillance “Alerts”
Decreased Susceptibility
![Page 40: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/40.jpg)
Geographic Distribution of Cephalosporin* Alerts , 2005
*Cefixime or Ceftriaxone
![Page 41: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/41.jpg)
Geographic Distribution of Cephalosporin* Alerts, 2006
*Cefixime or Ceftriaxone
![Page 42: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/42.jpg)
Geographic Distribution of Cephalosporin* Alerts, 2009
*Cefixime or Ceftriaxone
![Page 43: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/43.jpg)
San DiegoOrange Co.
Geographic Distribution of Cephalosporin* Alerts, 2010
*Cefixime or Ceftriaxone
![Page 44: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/44.jpg)
Proportion of GISP Participants Identified as Men who Have Sex with
Men (MSM), 1988–2010*
1988
1990
1992
1994
1996
1998
2000
2002
2004
2006
2008
2010
*05
101520253035
* Preliminary 2010 (Jan-Sept)Note: Among men with available sex of sex partner data
Percentage
Year
![Page 45: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/45.jpg)
Distribution of MICs to Azithromycin, 2006–2010*
≤0.03 0.06 0.125 0.25 0.5 1 2 4 8 1605
1015202530354045
20062007200820092010*
Perc
enta
ge o
f iso
late
s
Minimum Inhibitory Concentrations (MICs), µg/ml* Preliminary (Jan-Sept)
![Page 46: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/46.jpg)
Distribution of MICs to Azithromycin, 2006–2010*
2 4 8 160
0.05
0.1
0.15
0.2
0.25
0.3
0.35 20062007200820092010*
Perc
enta
ge o
f iso
late
s
Minimum Inhibitory Concentrations (MICs), µg/ml* Preliminary (Jan-Sept)
![Page 47: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/47.jpg)
INTERNATIONAL TRENDS
![Page 48: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/48.jpg)
Distribution of MIC for ceftriaxone, EURO-GASP, 2004–2009
European Center for Disease Prevention and Control (ECDC)http://www.ecdc.europa.eu/en/publications/Publications/1101_SUR_Gonococcal_susceptibility_2009.pdf
![Page 49: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/49.jpg)
Recent Timeline• Japan
– 2000: Possible treatment failure with cefdinir (oral) (MIC 1=µg/ml)
– Decreased susceptibility to cefixime (oral) in Japan -- 0% (1999) to 30% (2002)
– 2002–2003: 4 possible treatment failures with cefixime (oral)
– 2009: isolate with ceftriaxone MIC of 2 µg/ml (CSW)
• China – (2001–2009): ~30-40% isolates have MICs to
ceftriaxone of ≥ 0.06 µg/ml (~3% in US in 2010)• Europe
– 2009: Increases in ceftriaxone MICs from Europe – 2010:
• 2 treatment failures with cefixime (Norway)• 1 pharyngeal treatment failure with ceftriaxone (Norway)• 2 possible treatment failures with cefixime (England)
![Page 50: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/50.jpg)
Summary• “Alert” doesn’t mean resistance• Increasing MICs to cephalosporins (esp.
cefixime)– West– MSM
• Significance of higher MICs not yet known, but very concerning
• No treatment failures reported yet in US – Will be asking clinicians and HDs to
report treatment failures
![Page 51: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/51.jpg)
Response to Treatment Failures• Collect culture specimen for
susceptibility testing• Re-treat with at least 250 mg
ceftriaxone and 1-2 g azithromycin• Ensure partner treatment• Consider infectious disease
consultation• Report case to local health
department
![Page 52: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/52.jpg)
![Page 53: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/53.jpg)
ITS NOT JUST GONORRHEA……
![Page 54: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/54.jpg)
Chlamydia—Rates by County, United States, 2009
<300.0 (n = 2,052)
Rate per 100,000population
300.1–400.0 (n = 379)>400.0 (n = 710)
![Page 55: Infertility Prevention Project Region I Wells, Maine June 6-7, 2011](https://reader035.vdocuments.mx/reader035/viewer/2022062410/56816532550346895dd7b824/html5/thumbnails/55.jpg)
Questions?Thank you
For more information please contact Centers for Disease Control and Prevention
1600 Clifton Road NE, Atlanta, GA 30333Telephone: 1-800-CDC-INFO (232-4636)/TTY: 1-888-232-6348E-mail: [email protected] Web: http://www.cdc.gov
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
National Center for HIV/AIDS, Viral Hepatitis, STD , and TB PreventionDivision of STD Prevention